

Drug Prior Authorizationpalivizumab (SYNAGIS)

STEP 1: CLEARLY PRINT AND COMPLETE	TO EXPEDITE PROCESSING					
Date:	Prescriber First					
	& Last Name:					
Patient First	Prescriber NPI:					
& Last Name:						
Patient Address:	Prescriber Address:					
Patient ID:	Prescriber Phone:					
Patient Birth Date:	Prescriber Fax:					
STEP 2: COMPLETE REQUIRED CRITERIA						
Primary Diagnosis:	ICD 10 Code (REQUIRED) :					
REQUIRED FOR ALL:						
Prescriber is an NICU Physician, Neonatol	ogist or Pediatric Specialist					
(including Family Practice, General Pediatr	rics, Pediatric Pulmonology, Pediatric Cardiology)					
☐ DIAGNOSIS A: < 29 weeks, 0 days gestational age at birth AND < 12 months old at the start of RSV season						
Note: Max of 5 monthly do	ses or through end of RSV season					
☐ DIAGNOSIS B: < 32 weeks, 0 days gestational age AND chronic lung disease of prematurity (Defined as >21% oxygen required for at least the first 28 days after birth) AND < 12 months old at the start of RSV season						
Note: Max of 5 monthly do	ses or through end of RSV season					
weeks, 0 days gestational oxygen required for at least	age AND chronic lung disease of prematurity (> 21% st the first 28 days after birth) AND continue to require 6-month period prior to the start of the second RSV et following):					
chronic corticosteroid therapy:	Describe therapy:					
diuretic therapy:	Describe therapy:					
supplemental oxygen:	Describe therapy:					
Note: Max of 5 monthly do	ses or through end of RSV season					
☐ DIAGNOSIS D: Severe congenital abnorma	ality of airway OR severe neuromuscular disease that respiratory tract secretions AND < 12 months old at the					
Note: Max of 5 monthly doses or through end of RSV season						

09/12/2016 Version 1.0



☐ DIAGNOSIS E: Active diagnosis of hemodynamically significant heart disease (<i>Check one of the following conditions</i>) AND < 12 months old at start of RSV season									
	☐ CHF on medication ☐ Cyanotic heart disease								
	☐ Moderate to severe Pulmonary Hypertension								
Note: Max of 5 monthly doses or through end of RSV season. **Exception: one extra dose may be administered after surgery requiring cardiopulmonary bypass or extracorporeal membrane oxygenation									
The foll	owing groups of infants with CHD are not at increased risk of RSV and generally should not receive prophylaxis:								
-	 Infants and children with hemodynamically insignificant heart disease to include secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus 								
-	Infants with lesions adequately corrected by surgery, unless they continue to require medication for CHF								
-	Infants with mild cardiomyopathy who are not receiving medical therapy for this condition Children in the second year of life								
□ DIA	AGNOSIS F: Profoundly immunocompromised child (e.g., solid organ transplant, bone marrow transplant, or cancer chemotherapy) AND age < 24 months at the start of RSV season. Note: Max of 5 monthly doses or through end of RSV season								
	3: SPECIALTY PHARMACY REQUIRED								
	ella Specialty Pharmacy								
**Plea	se Complete the Specialty Medication Prescription Form on Page 3.								
STEP	4: SUBMISSION. SIGN AND FAX TO: PRIOR AUTHORIZATION 855-668-8551								
Presci	iber Signature: Date:								
If crite If appr	nt meets criteria, please allow 2 business days for processing ria not met, please submit chart documentation with form citing complex medical circumstances oved, coverage allowed as indicated above, subject to formulary changes estions, please call Navitus Customer Care at 1-866-333-2757								

Reference:

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. American Academy of Pediatrics. 2014

09/12/2016 Version 1.0



Specialty Medication Prescription Form

Fax completed Specialty Medication Request Form AND Prior Authorization Form to:

Prior Authorization, Fax Number: 855-668-8551

The Specialty Prescription Form will be forwarded if Prior Authorization is approved

PRESCRIBER II	NFORMATIO	ON						
Prescriber First &				Prescriber NPI:				
Last Name:	-							
Prescriber Fax:				Prescriber P	hone.			
T TOOOTIDOT T GX.				1 100011001 1	110110.			
Office Contact /				Prescriber				
RN Name:			Mailing Address:					
TW Traine.			maining / taa. 333.					
PATIENT INFOR	RMATION							
Please check on			☐ New	Patient	Refill	Request		
Patient First				Patient DOB	:	-		
& Last Name:								
Patient				Patient				
Daytime Phone:				Home Phone	e:			
Patient ID:				Group #:				
Height:				Weight:				
Primary				Allergies:				
Diagnosis:								
SHIPPING INFORMATION								
Ship Medication	ne Other							
Shipping Address								
(Street, City, State, Zip):								
PRESCRIPTION	INFORMAT	TION						
Drug Name	Strength	Instructions			Quantity	# of	Date	
						Refill(s)	Needed	

09/12/2016 Version 1.0

Date:

Prescriber Signature: _____